Viatris(VTRS)

CANONSBURG, PABiotechnology5 H-1B visas (FY2023)

Focus: Viatris (China) is a Shanghai-based generics and small-molecule company focused on COPD, cardiovascular, and CNS therapeutics with a diversified portfolio of post-LOE assets.

Oncology Cardiovascular Neurology Infectious Diseases

Profile data last refreshed 14h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Employees

30,000

Open Jobs

334+81 this month

Hot — 281 jobs added in 30d

Net +81 (281 new, 200 removed). Aggressive expansion phase.

Should You Work at Viatris?

AI assessment

Viable for commercial, regulatory, and operations professionals seeking stable generics-focused roles, but R&D and pipeline-betting careers should look elsewhere given zero trial activity.

Why Work Here

Strong commercial infrastructure with 202 open roles in sales and marketing, signaling aggressive market expansion in Asia-Pacific and beyond.

Data completeness

6/9 — Partial

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

5 imminent

ASTEPRO

Hiring

Stable

Revenue

$15.4B

FY2025

Key Products

WIXELA INHUB

COPD exacerbations in patients with history of exacerbations

$273M Part D

Post-LOE

Anchor franchise (32% of revenue); generic inhaled corticosteroid/LABA combination facing competitive pressure but stable Part D utilization.

Help build intelligence for Viatris

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diverse therapeutic portfolio across five high-demand areas (Oncology, Cardiovascular, Neurology, Infectious Diseases, Immunology) reducing single-therapy dependency.

Public company with established distribution and regulatory pathways offering career stability in a proven business model.

Watch Out For

Zero active clinical programs (0 Phase 1/2/3 trials) indicates minimal pipeline innovation and long-term product sustainability risk.
Patent cliff looming: RYTARY ($267M revenue) loses exclusivity 2028-12-26, threatening ~9% of apparent revenue base without pipeline replacement.
Recent WARN Act filing (May 2024, Canonsburg PA, 480 employees) signals operational restructuring; generics-market margin compression likely.

Generated by Claude from Viatris's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

RYTARY

Parkinson's disease

$267M Part D

LOE Approaching2.1yr

Second-largest revenue driver at risk; patent cliff in 4.7 years will eliminate exclusivity unless brand loyalty or formulation advantages sustain sales.

ARIPIPRAZOLE

Schizophrenia, Tourette's Disorder

$72M Part D

Post-LOE

Stable generic atypical antipsychotic with established market position; part of diversified portfolio across psychiatry.

LYRICA

Neuropathic pain, seizures, GAD, fibromyalgia

$72M Part D

LOE Approaching

Co-equal CNS franchise facing eventual LOE; controlled-substance status and high reimbursement support current revenue plateau.

PULMICORT FLEXHALER

Asthma, COPD

$36M Part D

LOE Approaching

Inhalation corticosteroid with established label; approaching LOE but smaller revenue base limits portfolio impact.

LIPITOR

Hypercholesterolemia

$33M Part D

LOE Approaching

Mature statin franchise well past primary patent cliff; declining revenue reflects generic saturation and GLP-1 competitive pressure.

SUNITINIB MALATE

Gastrointestinal stromal tumor, pancreatic neuroendocrine tumors

$31M Part D

Post-LOE

Generic oncology tyrosine-kinase inhibitor with niche indications; stable revenue reflects specialty cancer market utilization.

ALENDRONATE SODIUM

Postmenopausal osteoporosis, glucocorticoid-induced bone loss

$27M Part D

Post-LOE

Mature bisphosphonate franchise facing demographic headwinds and shifting osteoporosis treatment paradigm toward newer agents.

EFFEXOR XR

MDD, GAD, SAD, PD

$26M Part D

LOE Approaching

Extended-release SNRI with established psychiatric franchise; approaching LOE but sustained by brand loyalty and formulary positioning.

FENTANYL

Chronic pain, perioperative analgesia

$25M Part D

Pre-Launch

Opioid portfolio entry (pre-launch status unclear); potential growth offset by regulatory scrutiny and pain-management practice shifts toward multimodal approaches.

Pipeline & Clinical Trials

Eplerenone

Chronic Heart Failure

N/A

Clinical Trials (1)

NCT03342690Drug Use Investigation of Selara Tablets (an Investigation for Chronic Heart Failure)

N/A

No intervention

Schizophrenia

N/A

Clinical Trials (1)

NCT00448630An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics

N/A

no intervention

Glaucoma

N/A

Clinical Trials (1)

NCT01012245Non-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom

N/A

No intervention given in this observational study

Anterior Ischemic Optic Neuropathy

N/A

Clinical Trials (1)

NCT01260324Epidemiology Study of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

N/A

REVIparin-BRIDging-in a General Practice Setting in GErmany

Thromboembolism

N/A

Clinical Trials (1)

NCT02579122REVIparin-BRIDging-in a General Practice Setting in GErmany

N/A

Pregabalin

Neuropathic Pain

N/A

Clinical Trials (1)

NCT00843284Symptomatic Treatment Of Patients With Neuropathic Pain With LYRICA

N/A

Omacor Plus Standard Therapies In Post Myocardial Infarction (MI) Subjects Evaluation: The OPTIMISE

Myocardial Infarction (MI)

N/A

Clinical Trials (1)

NCT01632878Omacor Plus Standard Therapies In Post Myocardial Infarction (MI) Subjects Evaluation: The OPTIMISE Observational Study

N/A

Pregabalin

Neuropathic Pain

N/A

Clinical Trials (1)

NCT00892008A Post Marketing Surveillance Study On Pregabalin (Lyrica) On Efficacy, Safety And Tolerability Of Pregabalin

N/A

Atorvastatin Initiators

Cardiovascular

N/A

Clinical Trials (1)

NCT01304641Cardiovascular Events Based On Statin Initiation In The Elderly

N/A

Dydrogesterone

Endometriosis

N/A

Clinical Trials (1)

NCT02921763A Survey on Efficacy and Safety in Patients With Endometriosis

N/A

XALACOM

Glaucoma

N/A

Clinical Trials (1)

NCT01206361Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom

N/A

sildenafil

Pulmonary Arterial Hypertension

N/A

Clinical Trials (1)

NCT00866983Local Open-Label Access Study For Patients Who Completed A1481244 Study In Brazil

N/A

Lyrica

Neuralgia

N/A

Clinical Trials (1)

NCT00922987Clinical Study With Lyrica In Patients Suffering From Epilepsy

N/A

gabapentin

Epilepsies, Partial

N/A

Clinical Trials (1)

NCT01441401Safety and Efficacy of Gabapen for Pediatric (Regulatory Post Marketing Commitment Plan)

N/A

Ziprasidone

Schizophrenia

N/A

Clinical Trials (1)

NCT00579670Treatment of Schizophrenic Patients With Ziprasidone

N/A

Observational

Glaucoma,Open-Angle

N/A

Clinical Trials (1)

NCT00486252Non Interventional Study in Patients With Open Angle Glaucoma and/or Ocular Hypertension Treated With XALATAN®

N/A

Usual Care

Hypertension

N/A

Clinical Trials (1)

NCT00709787Epidemiological Study In Hypertensive Patients: Assessment Of Risk Factors Prevalence And Of Patients' Management

N/A

Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effe

HIV Infections

N/A

Gabapentin

Epilepsies, Partial

N/A

Clinical Trials (1)

NCT00567268Drug Use Investigation Of Gabapentin

N/A

intravesical sodium hyaluronate

Interstitial Cystitis and Bladder Pain Syndrome

N/A

Clinical Trials (1)

NCT05544695Real-world Evidence Study on Cystistat

N/A

Access program - sildenafil citrate, Viagra, Revatio

Pulmonary Arterial Hypertension

N/A

Clinical Trials (1)

NCT01582438An Open Label Access Study For Subjects Who Completed A1481156

N/A

Sertraline hydrochloride

Panic Disorder

N/A

Clinical Trials (1)

NCT00605917Special Investigation Of J Zoloft For Panic Disorder Patients

N/A

Latanoprost-timolol maleate fixed combination ophthalmic solution

Glaucoma

N/A

Clinical Trials (1)

NCT01191008Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension

N/A

sildenafil citrate

Pulmonary Arterial Hypertension

N/A

Clinical Trials (1)

NCT01365585Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension

N/A

Doxazosin mesylate GITS

Prostatic Hyperplasia

N/A

Clinical Trials (1)

NCT01003886A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH)

N/A

Observation of the Effects of Guideline-driven Lifestyle Interventions, Including Use of a Red-yeast

Hypercholesterolemia

N/A

Clinical Trials (1)

NCT05000541Observation of the Effects of Guideline-driven Lifestyle Interventions, Including Use of a Red-yeast Based Nutraceutical

N/A

sertraline

Posttraumatic Stress Disorder

N/A

Clinical Trials (1)

NCT01607593A Retrospective And Multicenter Survey To Investigate The Dosage, Efficacy And Safety Of Sertraline In Posttraumatic Stress Disorder Patients

N/A

Lipid Self Test

Hyperlipidemia

N/A

Clinical Trials (1)

NCT00828945Compliance With Treatment For Patients With Hyperlipidemia

N/A

Sertraline hydrochloride

Depression

N/A

Clinical Trials (1)

NCT00605813Special Investigation Of Long Term Use Of Sertraline.

N/A

Africa and Middle East Cardiovascular Epidemiological Study

Obesity

N/A

Clinical Trials (1)

NCT01243138Africa and Middle East Cardiovascular Epidemiological Study

N/A

ziprasidone

Affective Psychosis, Bipolar

N/A

Clinical Trials (1)

NCT00454883Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.

N/A

The Mycophenolate Pregnancy Registry

Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases

N/A

Selara

Hypertension

N/A

Clinical Trials (1)

NCT00749775Selara Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

N/A

There is no intervention in this study.

Glaucoma, Open-Angle

N/A

Clinical Trials (1)

NCT00334750Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada

N/A

Pancrelipase

Cystic Fibrosis

N/A

Clinical Trials (1)

NCT01427712Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

N/A

Tyrvaya

Dry Eye

N/A

Clinical Trials (1)

NCT07705893Treating Contact Lens Discomfort With Varenicline Solution Nasal Spray 0.03mg

N/A

Pregabalin

Neuralgia

N/A

Clinical Trials (1)

NCT01256593Safety And Efficacy Of Lyrica (Regulatory Post Marketing Commitment Plan)

N/A

Pregabalin

Pain Associated With Fibromyalgia

N/A

Clinical Trials (1)

NCT01773993Special Investigation of Pregabalin for Fibromyalgia (Regulatory Post Marketing Commitment Plan)

N/A

No intervention

Optic Neuropathy, Ischemic

N/A

Clinical Trials (1)

NCT00759174A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION

N/A

Xalacom

Glaucoma, Open-angle

N/A

Clinical Trials (1)

NCT00801437Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.

N/A

ID-Pain DN4 Questionnaire

Neuralgia

N/A

Clinical Trials (1)

NCT00599768Development and Validation for Taiwan Version ID Pain Questionnaire (ID Pain-T) and DN4 Questionnaire.

N/A

Patient adherence to national educational guidelines.

Heart Diseases

N/A

Clinical Trials (1)

NCT00415428A Quality Ensuring Project With Focus On Patients With Cardiovascular Diseases As Well As Type 2 Diabetes.

N/A

No Intervention

Cervical Pain

N/A

Clinical Trials (1)

NCT02868359PROs in Chronic Cervical Pain Patients With Accompanying Upper Limb Radiating Pain Treated With Pregabalin

N/A

Lipacreon

Exocrine Pancreatic Insufficiency

N/A

Clinical Trials (1)

NCT01427725Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency

N/A

Tolterodine tartrate

Overactive Bladder

N/A

Clinical Trials (1)

NCT01488578Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)

N/A

non-interventional

Bipolar Disorder

N/A

Clinical Trials (1)

NCT00584961BIMET Study: Evolution of Metabolic and Cardiovascular Risks Factors in Patients With Bipolar Disorder

N/A

Dymista

Allergic Rhinitis

N/A

Clinical Trials (1)

NCT05158972Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients

N/A

prior authorization

Fibromyalgia

N/A

Clinical Trials (1)

NCT01280747Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study

N/A

ziprasidone

Bipolar Disorder

N/A

Clinical Trials (1)

NCT01053429A Non-Interventional Post-Marketing Surveillance Study to Evaluate the Safety and Efficacy of Zeldox Capsule

N/A

SILDENAFIL

Pulmonary Hypertension

N/A

Clinical Trials (1)

NCT00666198Special Investigation For Long-Term Use Of Sildenafil (Regulatory Post Marketing Commitment Plan)

N/A

Interview Prep Quick Facts

Portfolio: 867 approved products, 148 clinical trials

Top TAs: Neurology, Cardiovascular, Oncology

H-1B (2023): 5 approvals

SEC Filings: 2 available

Open Roles: 334 active jobs

Portfolio Health

Pre-Launch96 (11%)

Launch5 (1%)

Growth3 (0%)

Peak23 (3%)

LOE Approaching95 (11%)

Post-LOE645

Therapeutic Area Focus

Neurology

135 marketed122 pipeline

Cardiovascular

156 marketed95 pipeline

Oncology

129 marketed7 pipeline

Infectious Diseases

93 marketed4 pipeline

Financials (FY2025)

Revenue

$15.4B5%

R&D Spend

$805M(5%)22%

Net Income

$55M

Hiring Trend

Actively Hiring

334

Open Roles

+51

Added

-40

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (1)

2024-05-10

480 employees affected— Canonsburg, PA

Source: state DOL filings, aggregated via Big Local News

2 active drug shortages

May 2024 WARN Act filing at Canonsburg, PA site (480 employees) for site consolidation indicates ongoing cost-restructuring and possible manufacturing footprint consolidation.

Adrenergic beta-Antagonists

66 marketed11 pipeline

Metabolic Diseases

35 marketed28 pipeline

Ophthalmology

24 marketed30 pipeline

Gastroenterology

43 marketed3 pipeline

Structural cost pressures evident; roles in consolidating manufacturing and operations are at elevated churn risk; commercial hiring may offset via geographic expansion.

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Viatris(VTRS)

Should You Work at Viatris?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (269)

Key Products by Revenue

Other Products (221)

Pipeline & Clinical Trials

Recent News · Viatris(10)

Open Jobs (334)

Production Operative

Associate Operator, Packaging - 2nd Shift

Professional (Senior) Sales Representative, Respiratory – Cape Coral, FL

Head of Global Engineering Steriles Operations

Professional (Senior) Sales Representative, Respiratory – Southern IL

Professional (Senior) Sales Representative, Respiratory – The Woodlands, TX

Sales Representative, Pain - Long Beach, CA

Senior Director – HR COEs, Global Talent Management

Sales Representative, Pain - Manassas, VA

Professional (Senior) Sales Representative, Pain - Memphis N, TN

Production Operative (12 month Agency Contract)

Senior Manager, Digital Marketing Strategy

Senior Chemist – 1st Shift

Supervisor, Pharmaceutical Coating – 5th Shift

Principal EPM Lead, IT Finance

Professional (Senior) Sales Representative, Pain - Philadelphia, PA

Supervisor Pharmaceutical Coating – 4th Shift

Professional (Senior) Sales Representative, Pain - New Orleans W, LA

Master Electrician, Main Maintenance – 2nd Shift

Master Electrician, Main Maintenance – 3rd Shift

Professional (Senior) Sales Representative, Pain - Ann Arbor, MI

Director – Portfolio Valuation & Decision Analysis

Senior Administrative Assistant – Global Launch Excellence

Microbiology Technician Level II

Professional (Senior) Sales Representative, Pain - Little Rock, AR

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (1)